Clinical Trial

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

Study acronym: MIRSEP
Recruiting
View on ClinicalTrials.gov →
Summary
Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-03
Trial Details
NCT Number NCT07597122
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Sepsis and Septic Shock
Enrollment 56 participants
Start Date 2026-06-01
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02